Cite
APA Citation
Richeldi, L., Fernández Pérez, E. R., Costabel, U., Albera, C., Lederer, D. J., Flaherty, K. R., Ettinger, N., Perez, R., Scholand, M. B., Goldin, J., Peony Yu, K., Neff, T., Porter, S., Zhong, M., Gorina, E., Kouchakji, E., & Raghu, G. (2020). pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, 8(1), 25–33. http://access.bl.uk/ark:/81055/vdc_100098439862.0x000010